Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Troglitazone

Catalog No: tcsc1634

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
97322-87-7

Formula:
$C_{24}H_{27}NO_5S$

Pathway:
Cell Cycle/DNA Damage;Autophagy

Target:
PPAR;Autophagy

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 100 mg/mL (226.48 mM)

Alternative Names:
CS-045

Observed Molecular Weight:
441.54

Product Description

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Troglitazone is a **PPARγ** agonist, with **EC_{50}**s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively.

IC50 & Target: EC50: 550 nM (Human PPARγ), 780 nM (Murine PPARγ)[1]

In Vitro: Troglitazone is a **PPARγ** agonist, with EC_{50}s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively[1]. Troglitazone (2-200 μM) is cytotoxic to the pancreatic cancer cell lines (MIA Paca2 and PANC-1 cells), with IC_{50}s of 49.9 ± 1.2 and 51.3 ± 5.3 μM, respectively. Troglitazone (50 μM) increases chromatin condensation in MIA Paca2 and PANC-1 cells, enhances the activity of caspase-3 and decreases Bcl-2 expression[2]. Troglitazone (0, 1, 2, and 4 μM) sensitizes TRAIL-mediated apoptosis in human lung adenocarcinoma cells. Troglitazone enhancement of TRAIL-induced apoptosis is blocked by inhibition of autophagy, via activation of autophagy flux. In addition, the effects of troglitazone are induced by PPARγ activation in A549 cells[3].

In Vivo: Troglitazone (200 mg/kg, p.o.) shows inhibitory effects on the growth of tumor in the MIA Paca2 xenograft model[2].